Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme returns betrixaban rights to Portola

Merck Sharpe and Dohme returns betrixaban rights to Portola

29th March 2011

Merck Sharpe and Dohme is to return the rights to the atrial fibrillation (AF) treatment betrixaban to its collaborative partner Portola Pharmaceuticals.

The company is transferring rights to the treatment, which is designed to prevent strokes among those affected by AF, back to Portola as part of a review of its investigational portfolio.

Merck and Portola have been working to jointly develop the drug since 2009 and have successfully advanced the compound to a phase III-ready stage, with earlier clinical data demonstrating its safety and efficacy.

Dr Luciano Rossetti, senior vice-president for global scientific strategy at Merck, said the decision has been taken due to its current prioritisation of late-stage therapies.

"Merck continues to advance its broad late-stage pipeline and remains committed to delivering medicines for cardiovascular disease," he said.

Earlier this month, it was announced that Merck Sharpe and Dohme will be allying with Lycera to develop new treatments for autoimmune disease.ADNFCR-8000103-ID-800478986-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.